この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2018/5/211 分で読めます
Cytomegalovirus in Transplantation: Developing Drugs To Treat or Prevent Disease; Draft Guidance for Industry; Availability
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Cytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease." The purpose of this guidance is to assist sponsors in all phases of development of drugs and biologics for the treatment or prevention of cytomegalovirus (CMV) disease in patients who have undergone solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT).
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →